Credit Suisse AG grew its holdings in Cellectis SA (NASDAQ:CLLS) by 9.2% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 420,667 shares of the biotechnology company’s stock after purchasing an additional 35,363 shares during the quarter. Credit Suisse AG owned approximately 1.01% of Cellectis worth $11,871,000 at the end of the most recent quarter.
Other hedge funds have also added to or reduced their stakes in the company. FMR LLC grew its position in shares of Cellectis by 18.0% in the second quarter. FMR LLC now owns 4,240,010 shares of the biotechnology company’s stock valued at $119,949,000 after purchasing an additional 647,164 shares during the last quarter. JBF Capital Inc. acquired a new stake in shares of Cellectis in the second quarter valued at approximately $1,697,000. ARK Investment Management LLC grew its position in shares of Cellectis by 178.8% in the second quarter. ARK Investment Management LLC now owns 244,263 shares of the biotechnology company’s stock valued at $6,910,000 after purchasing an additional 156,666 shares during the last quarter. BlackRock Inc. grew its position in shares of Cellectis by 259.7% in the second quarter. BlackRock Inc. now owns 443,713 shares of the biotechnology company’s stock valued at $12,552,000 after purchasing an additional 320,340 shares during the last quarter. Finally, Vident Investment Advisory LLC grew its position in shares of Cellectis by 30.3% in the second quarter. Vident Investment Advisory LLC now owns 80,527 shares of the biotechnology company’s stock valued at $2,278,000 after purchasing an additional 18,730 shares during the last quarter. Institutional investors and hedge funds own 27.68% of the company’s stock.
Shares of CLLS opened at $20.25 on Friday. Cellectis SA has a 1 year low of $20.15 and a 1 year high of $38.85.
Several research firms have recently commented on CLLS. ValuEngine upgraded shares of Cellectis from a “hold” rating to a “buy” rating in a research report on Tuesday, September 18th. BidaskClub upgraded shares of Cellectis from a “sell” rating to a “hold” rating in a research report on Saturday, October 6th. Finally, Zacks Investment Research upgraded shares of Cellectis from a “hold” rating to a “buy” rating and set a $25.00 price target on the stock in a research report on Friday, November 16th. One research analyst has rated the stock with a sell rating, three have given a hold rating and three have issued a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $48.00.
WARNING: “Credit Suisse AG Grows Stake in Cellectis SA (CLLS)” was first posted by American Banking News and is owned by of American Banking News. If you are viewing this article on another publication, it was illegally stolen and republished in violation of US and international copyright and trademark laws. The original version of this article can be viewed at https://www.americanbankingnews.com/2018/12/08/credit-suisse-ag-grows-stake-in-cellectis-sa-clls.html.
Cellectis SA, a clinical stage biotechnological company, develops and sells immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer in France. The company operates through two segments, Therapeutics and Plants. Its lead product candidate is UCART19, an allogeneic T-cell product candidate for the treatment of CD19 expressing hematologic malignancies, which develop in acute lymphoblastic leukemia (ALL).
Further Reading: How Do You Calculate Return on Equity (ROE)?
Want to see what other hedge funds are holding CLLS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cellectis SA (NASDAQ:CLLS).
Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.